Acrivon Therapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $7.9M | $106.6M | $99.6M |
| FY2022 | $10.8M | $181.2M | $29.5M |
| FY2023 | $17.1M | $138.3M | $36.0M |
| FY2024 | $19.8M | $196.6M | $39.8M |
| FY2025 | $17.2M | $129.7M | $41.5M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $7.9M | $106.6M | $99.6M |
| FY2022 | $10.8M | $181.2M | $29.5M |
| FY2023 | $17.1M | $138.3M | $36.0M |
| FY2024 | $19.8M | $196.6M | $39.8M |
| FY2025 | $17.2M | $129.7M | $41.5M |